Elevance Health's Q2 2025 earnings report highlights a mix of financial growth and operational challenges. The company reported a significant increase in operating revenue year-over-year, driven by higher premium yields and recent acquisitions in its Health Benefits and Carelon segments. However, net income and diluted EPS saw a decrease, primarily due to elevated medical cost trends, particularly within their Medicaid business and Affordable Care Act (ACA) health plans. Despite these cost pressures, Elevance Health reaffirmed its adjusted diluted EPS guidance for the full fiscal year 2025 and returned capital to shareholders through share repurchases and dividends, demonstrating confidence in its long-term strategy and diversified business model. The report also details segment-specific performance, noting strong growth in Carelon while Health Benefits faced membership attrition in Medicaid.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related